Kalaris Therapeutics Overview
Latest ROE for Kalaris Therapeutics: -76.75% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-76.75%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, KLRS shows a ROE of -76.75%. That is below the Healthcare sector average of 21.28%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 21.28%. Kalaris Therapeutics is at -76.75%, which is lower that average. That is roughly 460.7% below the sector mean. Use the comparison chart on this page to see how KLRS stacks up against individual peers as well.
Check the historical chart to see whether KLRS's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Kalaris Therapeutics with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Kalaris Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently -76.75%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 21.28%, while KLRS is at -76.75%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
